Changing Trends in GLP-1 Drug Use: Who's Taking Them and Why?
Krissy Vann | Host, All Things Fitness and Wellness
In recent years, there has been a notable increase in the use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists), not only for managing type 2 diabetes but also as a tool for weight loss. Medications like Ozempic and Wegovy, which were initially designed for diabetes management, have gained widespread attention for their weight loss benefits. This surge in demand has led to global shortages of these drugs, affecting those who rely on them for diabetes care.
A new study published in the Annals of Internal Medicine explored this trend, examining the changing patterns of GLP-1 agonist prescriptions across the United States. Researchers from Cedars-Sinai and other institutions conducted a comprehensive analysis using data from around 45 million individuals who had medical visits between 2011 and 2023. The study revealed that among the approximately one million new GLP-1 agonist users identified, there was a notable increase in usage among individuals without type 2 diabetes. Specifically, there was a twofold increase in prescriptions for those with a body mass index of 30 or greater, as well as for those with a BMI of 27 to 30 accompanied by obesity-related conditions.
Dr. Ali Rezaie, co-first author of the study and medical director of the Cedars-Sinai GI Motility Program, commented on the findings: "Essentially, after the medication was approved for obesity, GLP-1RA use took off so quickly that we lost control and vision of how fast people were picking up these medications, and the trends of use are uncertain." The study also found that the proportion of GLP-1 agonist users without FDA-approved indications rose from 0.21% in 2019 to 0.37% in 2023.
Dr. Yee Hui Yeo, another co-first author and clinical fellow at Cedars-Sinai, highlighted the implications of these trends: "This data suggests that more healthcare providers are seeing the benefits of these medications for treating obesity, which is a significant public health shift. However, it also raises concerns about potential medication shortages and the need to ensure that patients with diabetes still have access to these treatments."
The study's findings underscore the growing popularity and demand for GLP-1 agonists and highlight the need for healthcare policies that promote equitable access to these essential treatments.
Elevate Your Expertise: Tune in to Our YouTube Channel for Exclusive Podcasts with fitness and wellness Industry Titans and Game-Changers
